133442Prostate Cancer Chemotherapy Precision Dosing APPClosedFeasibility StudiesInnovate UK"Precision medicine heralds a new era of cancer care where each patient receives the right drug at the right dose and time specific to their needs. However, the practice of precision dosing is hampered by a lack of smart dosing algorithms. The choice of chemotherapy dose in the clinical practice is predominantly based on Body Surface Area (BSA) which is derived from a population based analysis. This can lead to under or over dosing a significant number of cancer patients; hence there is currently no reliable process for defining the optimal dosing regimen on an individual patient basis. Focusing on prostate cancer in this feasibility study, our goal is to develop a demonstrator for Precision Dosing within oncology. It will integrate a diverse range of drug, tumour and patient data curently monitored in curent clinical pratice in order to better design dosing regimen, optimise patient care path, and ultimately deliver improved cancer care. To achieve our goal we will integrate existing tools (clinical PK/PD efficacy and toxicity models) to build this novel predictive platform. Also in collaboration with the Oxford AHSN we will build a business plan for implementation within the NHS (""Route to Market""). This will serve as a basis of a development plan to take forward the proposed Precision Dosing APP demonstrator into a fully commercial version."